Metformin: Anti Aging Drug? (David Sinclair Book LIFESPAN – Part 4)

Metformin: Anti Aging Drug? (David Sinclair Book LIFESPAN – Part 4)

October 31, 2019 7 By Jose Scott


So this is part 4 in the series on
LIFESPAN, the new book by David Sinclair. I’m having a blast on it because he
covers articles… he covers items that I’ve done videos on. This one I’m very
passionate about metformin and anti-aging. This is the TAME study. This is Nir
Barzilai. TAME stands for “Targeting Aging with Metformin.” Dr. Barzilai is the
principal investigator, but as I’ve said many times, there were dozens of
gerontologists (people that study aging) involved in the development of this study.
Now why would we want to use metformin for anti-aging? What
they’re looking for is a composite outcome things, like decrease eye disease,
decreased kidney disease, decreased cancer, decreased heart disease, decreased
stroke, decrease cognitive decline. So hopefully that begins to make the
point why metformin is the most widely prescribed anti-diabetic medication in the world. And it decreases hepatic gluconeogenesis. However, as David Sinclair would say, it
also up right-up regulates or amps up AMPK. Now, why is AMPK an issue? And why is
David Sinclair focusing on it? Well, this is an overview of all of the places in
the metabolism where metformin impacts different places that drive aging, like
TNF (Tumor Necrosis Factor alpha), IGF (insulin-like growth factor),
insulin and it’s a receptor AMPK. David Sinclair mentions in his book mTOR
as I think is mentioned in the book and we’ve mentioned multiple other places as
well. These are all SIRT1. David Sinclair discovered the SIRT enzymes
which again are very involved in driving the epigenetics and the metabolism
associated with insulin resistance and broader aging components. So this is just
another quick look from a recent article in the New England Journal. It
mentions AMPK and insulin resistance, insulin and insulin-like growth
factor. This article you may recognize is on autophagy. So again,
hopefully helping connect quite a few dots here. Again, why metformin? As I’ve
said before, it’s been used safely for over 60 years. It’s associated with
decreased cancer, decreased cognitive decline, and all those other diseases that
we mentioned. How did they develop a composite outcome? Again, they wanted
things that were age-related, common in populations, and created a
significant health risk. Again, I’m not going to repeat the different items that
were included. When you look at 3 of the key diseases that we’re talking
about (and I’ve already mentioned them), they are already associated with
decreased problems when you’re taking metformin. Here’s an example.
Observational studies metformin and cardiovascular outcomes. We saw that in
the MACE study the VA/Medicare… I’m sorry… the VA/Medicare database, Canadian study,
REACH study. the VA patients study cancer. As you see on this, I think this is
called Christmas tree plot. Multiple studies out there showing that
people that were on metformin were on this left side of this vertical line.
What does that mean? That means they were less likely to get cancer.
How about cognitive decline? Again, multiple studies with the Singapore
Longitudinal Aging Study, Cheng with the Taiwan database, Hsu with health
insurance in Taiwan, several others. Again, decreased dementia associated with use
of metformin all cause mortality. In other words, remember I talked about
we’ve talked about this before in other studies, something may have a huge
positive impact on cardiovascular disease ver since. Even though heart
attacks and strokes are only… they are the number one… and what number three
cause of death? They still only cause about a third of deaths overall, so you’d
have to have a huge impact for something that decreases heart attack and
stroke and also decreases total mortality. That’s exactly what you
see with metformin. Again, underlining the strength of the association with
anti-aging and positive impacts using this medication, there’s other components.
I’ve already mentioned these before. This is repetitive. The TAME study design.
They’re looking at 850 milligrams two times a day, and it’s a double-blind
randomized placebo-controlled trial. So you can’t get any better in terms of the
type of study. Now, what’s the inclusion criteria? Unfortunately, they’re looking
at people 65 to 79. I think they’re waiting too late. David Sinclair, for
example, started taking metformin in his late 40s. I started taking it in my
mid-50s, late fifties. Where’s the TAME study now? Well, this is like the third or
fourth video overall out of over 600. So don’t that I’ve done on time. So again
I’ve done three or four. If you don’t remember them, don’t worry about it, we’ve
covered most of the materials here. Here’s the problem. I don’t think it’s
completely fun to do. This is a Forbes article on the TAME study from February
of this year. In our first videos two years ago, we talked about how it
couldn’t be. It wasn’t being funded yet and how the
NIH was fighting it. Because it’s against aging. And they can’t find something
that’s against aging. They can only fund countermeasures against disease. So kind
of weird. But Barzilai was fighting the good fight now about a year ago. We
heard that it got funded. Haven’t heard the results though, and this may be
why. If you look at the rest of this Forbes article from February and AMFAR (the
American Federation for Aging Research) has committed 35 million
dollars to it. They’re hoping for another 40 million from NIH.
However, NIH is still dragging its feet. Because it’s not a disease. It’s
anti-aging. Obviously, you know, the obvious question comes up, “Why don’t they
just label it as one of these diseases?” I’m not there.
I’m not involved in that battle. Anyhow, one other thing that we can say is that
the Big Pharma are not involved in funding this heck. Why would they? Who’s
gonna make any money off that form? It doesn’t make sense to them. But it does
make sense to me, and it’s unfortunate that so few people have
investigated this more deeply. This was a long video. I appreciate your interest,
especially if you’ve made it this far. So I’m very excited to announce we now have
a membership page. Now, what is that? That’s the one place where you can go
and access all of our digital products. It starts off with a few free things,
like a lot of infographics which help you understand the basics of insulin
resistance, cardiovascular inflammation, and other key concepts on how to prevent
heart attack and stroke. The next free item is the intro and first chapter of
the book that we’re writing on plaque and the standards of medicine just
aren’t doing very well right now in terms of the number one killer and
disabler – plaque. We don’t do a good job of measuring it, we don’t do a good job
of monitoring it, and there are better ways. So that’s what this book is all
about. Again, go in, get a free a look at the intro and in the first chapter. And
if you’ve purchased the cardiovascular inflammation and IR courses, thank you so
much for doing that. You purchased those at a time before we had them totally
cleaned up. And we’ve cleaned them up now, and they’re available for you right
there on the membership page. Hit the link below, register and go in, and take a
look. Look forward to seeing you there. Thank you.